){kind=logo}
Loeb & Loeb is mentioned in a press released published on GlobeNewswire for representing Mountain Crest V, a special purpose acquisition company, in its business combination with CubeBio, a South Korean cancer diagnostics technology company.
CubeBio has a pre-transaction equity value of $375 million, and the deal expected to close in the first quarter of 2025.
For more information, please see the companies’ joint press release.
CubeBio has a pre-transaction equity value of $375 million, and the deal expected to close in the first quarter of 2025.
For more information, please see the companies’ joint press release.